Acute myocardial infarction occurring in versus out of the hospital: patient characteristics and clinical outcome  by Zahn, Ralf et al.
Acute Myocardial Infarction Occurring
In Versus Out of the Hospital:
Patient Characteristics and Clinical Outcome
Ralf Zahn, MD, Rudolf Schiele, MD, Karlheinz Seidl, MD, Thomas Kapp, MD,*
Hans Georg Glunz, MD,† Edwin Jagodzinski, MD,‡ Thomas Voigtla¨nder, MD,§ Martin Gottwik, MD,\
Gunther Berg, MD,¶ Helmut Thomas, MD,# Jochen Senges, MD, FOR THE Maximal Individual TheRapy
in Acute Myocardial Infarction (MITRA) Study Group**
Ludwigshafen, Speyer, Kaiserslautern, Mainz, Nu¨rnberg, Homburg/Saar, Bad Du¨rkheim, Germany
OBJECTIVES We describe the baseline characteristics and clinical course of patients who had an acute
myocardial infarction (AMI) during their hospital stay.
BACKGROUND In comparison with patients who had an AMI outside of the hospital (prehospital AMI), the
data on patients who had an AMI in the hospital are poorly described.
METHODS Patients with an in-hospital AMI were prospectively registered in the Southwest German
Maximal Individual TheRapy in Acute myocardial infarction (MITRA) study and compared
with patients with prehospital AMI.
RESULTS Of 5,888 patients with AMI, 403 patients (6.8%) had an in-hospital AMI. These patients
were older, more often male and sicker as compared with the patients with a prehospital AMI.
They also showed a higher prevalence of concomitant diseases, such as arterial hypertension,
diabetes mellitus, renal insufficiency and contraindications for thrombolysis. There was no
significant difference regarding the use of reperfusion therapy, either thrombolysis (in-
hospital AMI 44.2% vs. prehospital AMI 49.1%; odds ratio [OR] 0.86, 95% confidence
interval [CI] 0.70 to 1.05) or primary angioplasty (9.9% vs. 8.2%; OR 1.23, 95% CI 0.88 to
1.73), or a combination of both, between the two groups. The interval from symptom onset
to the start of treatment in patients receiving reperfusion therapy was 55 min for patients with
an in-hospital AMI versus 180 min for patients with a prehospital AMI (p 5 0.001).
In-hospital death occurred in 110 (27.3%) of 403 patients with an in-hospital versus 762
(13.9%) of 5,485 patients with a prehospital AMI (OR 2.33, 95% CI 1.85 to 2.94). This was
confirmed by logistic regression analysis after adjusting for other confounding variables (OR
1.67, 95% CI 1.23 to 2.24).
CONCLUSIONS In-hospital AMI occurred in 6.8% of patients. Time to intervention was shorter; however, the
use of reperfusion therapy for in-hospital AMI was not different from that for prehospital
AMI. In particular, primary angioplasty seems to be underused in these patients. This, as well
as the selection of patients, may result in the high hospital mortality rate of 27.3%. (J Am
Coll Cardiol 2000;35:1820–6) © 2000 by the American College of Cardiology
Case fatality from acute myocardial infarction (AMI) in the
general population is about twice as high as that in the
hospital population of patients reaching the hospital alive
(1–3). Acute myocardial infarction occurring in patients
already admitted to the hospital (in-hospital infarction) may
represent a selected subgroup of sicker patients, such as
those with postoperative AMI (4–6), postinterventional
(balloon angioplasty, stent implantation) AMI (7,8) or AMI
after unstable angina pectoris. However, these patients
should offer the opportunity for insights into the difference
between the general population and the hospital population
of case fatality in AMI, especially if there is still a difference
even though early diagnosis and therapy should be possible
with in-hospital AMI.
A search in Medline from 1980 to 1999 resulted in only
two reports on in-hospital infarctions (9,10). The study by
Zmyslinski et al. (9) was published before the era of
reperfusion therapy, and the study by L’Abbate et al. (10)
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focused on preinfarction features. Each report provided data
on only 50 patients with in-hospital Q wave AMI. There-
fore, we used the data of the Southwest German Maximal
Individual TheRapy in Acute myocardial infarction
(MITRA) study (11) to analyze the proportion and clinical
course of patients with in-hospital versus prehospital AMI.
METHODS
The MITRA study was a prospective, multicenter, obser-
vational study of the current treatment of AMI in Germany
(11). Fifty-four hospitals in Southwest Germany partici-
pated in the study, including university hospitals, tertiary-
care centers and smaller hospitals. All patients presenting
within the first 96 h of the onset of pain were registered
prospectively, as soon as the diagnosis of AMI had been
made. Recruitment of patients started in June 1994 and
ended in January 1997.
Acute myocardial infarction was diagnosed on the basis of
the two following criteria: 1) persistent angina pectoris for
$20 min 2) ST segment elevation of $1 mm in at least two
standard leads or $2 mm in at least two contiguous
precordial leads; or the presence of left bundle branch block.
It was later confirmed by the elevation of cardiac enzymes of
more than twice the normal upper range.
Definitions. Postinfarction angina was diagnosed in the
presence of new angina pectoris within two weeks after
myocardial infarction. Reinfarction was defined as recurrent
chest pain lasting .20 min with either new ST segment
elevation, emergency angiographic confirmation of a reoc-
cluded vessel or recurrent elevation of cardiac enzymes.
Minor stroke was defined as a transient cerebral ischemia;
major stroke as a persistent cerebral ischemia. A combined
clinical end point was defined by the occurrence of death,
reinfarction or stroke. Patients were prospectively classified
as being eligible for thrombolysis after exclusion of patients
with either a nondiagnostic first electrocardiogram (ECG)
or contraindications for thrombolysis (e.g., recent surgery or
trauma ,14 days, recent cerebral infarction ,3 months or
active bleeding).
For this analysis, patients who had an AMI during their
hospital stay (in-hospital infarction) were compared with
patients who had an AMI outside of the hospital and
showed a prehospital delay of #12 h (prehospital infarc-
tion). Patients who had an AMI during or within 24 h after
coronary angiography, percutaneous transluminal coronary
angioplasty or stent implantation were regarded as having
in-hospital infarctions. Patients initially registered as having
a prehospital infarction and who subsequently had an
in-hospital reinfarction were not included as the in-hospital
infarction group. Admission diagnosis was not evaluated,
according to the study protocol, in patients with an in-
hospital AMI. Of the 54 participating hospitals, four
performed a chart review to define the admission diagnosis.
Admission diagnosis was available in 88 (21.8%) of 403
patients with an in-hospital AMI.
Statistics. DATA COLLECTION. Data on the prehospital
period and the early in-hospital period (first 48 h) were
collected within the first two to three days in the intensive
care unit. Clinical events occurring thereafter were regis-
tered on a separate record form on hospital discharge. Each
participating center had committed, by written consent, to
include each patient with an AMI during the study period.
The patients gave written, informed consent for processing
their anonymous data. All data sheets were sent to the
central data processing center (Department of Cardiology,
Heart Center Ludwigshafen) for uniform monitoring and
registration.
DATA ANALYSIS. Absolute numbers and percentages were
computed to describe the patient group. Median values and
25% and 75% percentiles were computed. Categoric values
were compared by chi-square analysis or the Cochran-
Mantel-Haenszel test, and the odds ratio (OR) and 95%
confidence interval (CI) were computed. Continuous vari-
ables were compared by the two-tailed Wilcoxon rank-sum
test. Multiple logistic regression was used to analyze factors
influencing hospital mortality and the combined end point.
The variables examined included age, gender, location of
infarction, previous infarction, presence of heart failure on
hospital admission, systolic blood pressure, heart rate, bun-
dle branch block, concomitant diseases, concomitant med-
ications, thrombolytic eligibility and the occurrence of an
infarction in or out of the hospital. P values ,0.05 were
considered significant. All p values are two-tailed. The tests
were performed using the SAS statistical package, version
6.12 (Cary, North Carolina).
RESULTS
Selection of patients from the MITRA trial is shown in
Figure 1. Of 5,888 patients with AMI, 403 (6.8%) had an
in-hospital AMI and 5,485 (93.2%) had a prehospital
AMI. The baseline characteristics of the patients are
shown in Table 1. Patients who had an in-hospital AMI
were older, more often male and sicker as compared with
patients with a pre-hospital AMI. The first ECG was less
often diagnostic in patients with an in-hospital AMI
(64.2% vs. 72.6%; OR 0.68, 95% CI 0.55 to 0.84). These
patients also showed a higher prevalence of concomitant
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CI 5 confidence interval
ECG 5 electrocardiogram
MITRA 5 Maximal Individual TheRapy in Acute
myocardial infarction study
MONICA 5 Multinational MONitoring of Trends and
Determinants in CArdiovascular Disease
OR 5 odds ratio
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diseases, such as arterial hypertension, diabetes mellitus
and renal insufficiency. In addition, they more often had
contraindications for thrombolysis, such as a history of
ulceration, active bleeding, a recent cerebral infarction or
a recent trauma or surgery.
Admission diagnoses were retrospectively evaluated in 88
(21.8%) of 403 patients with an in-hospital AMI (Fig. 2).
Most patients (72.8%) were admitted to the hospital with
either stable or unstable angina pectoris. A minority of
patients (8%) had a postoperative AMI. Concomitant med-
Figure 1. Selection of patients from the MITRA trial.
Figure 2. Admission diagnosis in 88/403 (21.8%) of patients with
in-hospital myocardial infarction.
Table 1. Baseline Characteristics of the Patients
In-Hospital
Infarction Group
(n 5 403)
Prehospital
Infarction Group
(n 5 5,485)
Odds Ratio (95%
CI) or p Value
Age (years) 70 (61/74) 66 (56/74) 0.001
Male gender 224/402 (55.7%) 3,696/5,484 (67.4%) 0.61 (0.50–0.75)
Anterior wall myocardial
infarction
214/390 (54.9%) 2,589/5,371 (48.2%) 1.31 (1.06–1.61)
Previous infarction 147/401 (36.7%) 849/5,462 (15.5%) 3.15 (2.53–3.90)
Heart failure on admission 58/401 (14.5%) 461/5,462 (8.4%) 1.83 (1.37–2.46)
Cardiogenic shock (before
treatment)
15/291 (5.2%) 161/4,291 (3.8%) 1.39 (0.81–2.40)
Resuscitation 24/291 (8.3%) 277/4,291 (6.5%) 1.30 (0.84–2.01)
Systolic blood pressure
(mm Hg)
130 (110/150) 140 (120/150) 0.021
Heart rate (beats/min) 84 (70/100) 80 (68/96) 0.011
Left bundle branch block 21/393 (5.3%) 278/5,410 (5.1%) 1.04 (0.66–1.64)
Right bundle branch block 21/393 (5.3%) 263/5,410 (4.9%) 1.11 (0.70–1.74)
Atrial fibrillation 22/290 (7.6%) 313/4,258 (7.4%) 1.04 (0.66–1.62)
First diagnostic ECG 258/402 (64.2%) 3,973/5,473 (72.6%) 0.68 (0.55–0.84)
Concomitant diseases
History of ulcer or active
bleeding
29/403 (7.2%) 297/5,485 (5.4%) 1.35 (0.91–2.01)
Recent (,3 months)
cerebral infarction
12/401 (3%) 64/5,462 (1.2%) 2.6 (1.39 4.86)
Recent (,14 days)
surgery or trauma
28/401 (7%) 53/5,462 (1%) 7.66 (4.79–12.23)
Renal insufficiency 33/401 (8.2%) 179/5,462 (3.3%) 2.65 (1.80–3.89)
Chronic obstructive lung
disease
15/401 (3.7%) 209/5,462 (3.8%) 0.98 (0.57–1.67)
Arterial hypertension 143/291 (49.1%) 1,543/4,291 (36%) 1.72 (1.36–2.18)
Diabetes mellitus 76/291 (26.1%) 897/4,291 (20.9%) 1.34 (1.02–1.76)
Data are presented as the median value (25th/75th percentiles) or the number (%) of patients.
CI 5 confidence interval; ECG 5 electrocardiogram.
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ications during the first 40 h after hospital admission or after
diagnosis of AMI, reperfusion therapy and the different
time intervals are shown in Table 2. There was no signifi-
cant difference regarding the use of reperfusion therapy,
either thrombolysis (in-hospital AMI 44.2% vs. prehospital
AMI 49.1%; OR 0.86, 95% CI 0.70 to 1.05) or primary
angioplasty (in-hospital AMI 9.9% vs. prehospital AMI
8.2%; OR 1.23, 95% CI 0.88 to 1.73), or a combination of
these, between the two groups. The proportion of
thrombolytic-eligible patients was significantly lower in the
patients with an in-hospital AMI (59.3% vs. 74.3%; OR
0.51, 95% CI 0.41 to 0.62). However, there was no
difference in the proportion of patients receiving no reper-
fusion therapy or in the proportion of patients treated with
thrombolysis in thrombolytic-eligible patients. Patients
with an in-hospital AMI were less likely to be treated with
any of the adjunctive medications.
Patients with an in-hospital AMI were admitted to the
hospital 2.5 days (median) before the onset of AMI. The
interval from the onset of symptoms to the start of reper-
fusion therapy was 55 min (median) for patients with an
in-hospital AMI versus 180 min (median) for patients with
a prehospital AMI (p , 0.001). Almost all clinical events
were more frequent in the in-hospital AMI group (Table 3).
In-hospital death occurred in 110 (27.3%) of 403 patients
with an in-hospital AMI versus 762 (13.9%) of 5,485
patients with a prehospital AMI (OR 2.33, 95% CI 1.85 to
2.94), and the combined end point occurred in 58.6% versus
41.4% (OR 2.0, 95% CI 1.63 to 2.47). Logistic regression
analysis showed that in-hospital AMIs were independently
associated with a higher mortality (OR 1.67, 95% CI 1.23 to
2.24) and a higher incidence of the combined end point
(OR 1.67, 95% CI 1.28 to 2.18), after adjusting for other
confounding variables. Patients treated with primary angio-
plasty had the best outcome, followed by those with the
combination of angioplasty and thrombolysis and throm-
bolysis alone. Patients not treated with reperfusion therapy
had the highest rate of mortality and morbidity (Table 4).
Of the 54 participating hospitals, eight had the facilities
to perform angioplasty. These eight hospitals had a higher
proportion of in-hospital AMIs in relation to all of their
AMIs—7.9% (136 of 1,717) versus 6.4% (267 of 4,171)
(OR 1.26, 95% CI 1.02 to 1.56)—as compared with
hospitals without these facilities. The proportion of patients
with an in-hospital AMI not treated with reperfusion
therapy was not significantly different between the two types
of hospitals—those with angioplasty facilities (52 [38.2%] of
136 patients) and those without angioplasty facilities (123
[46.1%] of 267 patients) (OR 0.73, 95% CI 0.48 to 1.10).
More patients with an in-hospital AMI were lytic eligible at
Table 2. Time Intervals, Reperfusion Therapy and Concomitant Medications Within the First 48 Hours
In-Hospital
Infarction Group
(n 5 403)
Prehospital
Infarction Group
(n 5 5,485)
Odds Ratio (95%
CI) or p Value
Time intervals
Hospital admission to start of
symptoms (h)
60.7 (16/173) — —
Prehospital delay (min) — 165 (90/420) —
In-hospital time to treatment (min) 55 (30/120)* 35 (25/65)† —
Onset of symptoms to start of
treatment (min)
55 (30/120) 180 (120/300) 0.001
Reperfusion therapy
None (i.e., conservative) 175/403 (43.4%) 2,287/5,485 (41.7%) 1.07 (0.88–1.32)
Intravenous thrombolysis 178/403 (44.2%) 2,636/5,485 (49.1%) 0.86 (0.70–1.05)
Primary angioplasty 40/403 (9.9%) 451/5,485 (8.2%) 1.23 (0.88–1.73)
Thrombolysis and angioplasty 10/403 (2.5%) 111/5,485 (2%) 1.23 (0.64–2.37)
Reperfusion therapy in thrombolytic-
eligible patients‡
Thrombolytic-eligible patients§ 239/403 (59.3%) 4,074/5,485 (74.3%) 0.51 (0.41–0.62)
None (i.e., conservative) 76/239 (31.8%) 1,302/4,074 (32%) 0.99 (0.75–1.31)
Intravenous thrombolysis 128/239 (53.6%) 2,319/4,074 (56.9%) 0.87 (0.67–1.13)
Concomitant medications during first 48 h
Heparin 363/398 (91.2%) 5,132/5,448 (93.2%) 0.64 (0.44–0.92)
Intravenous nitroglycerin 307/398 (77.1%) 4,545/5,441 (83.5%) 0.67 (0.52–0.85)
Aspirin 342/400 (85.5%) 5,169/5,482 (94.3%) 0.36 (0.26–0.48)
Beta-blockers 176/400 (44%) 2,929/5,477 (53.5%) 0.68 (0.56–0.84)
ACE inhibitors 191/400 (47.8%) 2,788/5,476 (50.9%) 0.88 (0.72–1.08)
*Start of symptoms to treatment. †Admission at the hospital to treatment. ‡Excluded were patients with either a nondiagnostic first electrocardiogram or contraindications for
thrombolysis—recent surgery or trauma ,14 days, recent cerebral infarction ,3 months or active bleeding.
Data are presented as the median value (25th/75th percentile) or number (%) of patients.
ACE 5 angiotensin-converting enzyme; CI 5 confidence interval.
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hospitals with angioplasty facilities (97 [71.3%] of 136 vs.
142 [52.2%] of 267 patients). However, also in lytic-eligible
patients, the proportion of those receiving no reperfusion
therapy was not different (32 [33%] of 97 patients in
angioplasty facilities vs. 44 [31%] of 142 patients in no-
angioplasty facilities). (OR 1.10, 95% CI 0.63 to 1.91).
Primary angioplasty was used more often at hospitals with
angioplasty facilities (35 [25.7%] of 136 vs. 5 [1.9%] of 267
patients) (OR 18.2, 95% CI 6.92 to 47.65). Nevertheless,
there was no difference in clinical outcome in patients with
in-hospital infarctions between the two types of hospitals
(hospital mortality 26.5% [36 of 136 patients] vs. 27.7% [74
of 267 patients]) (OR 0.94, 95% CI 0.59 to 1.50) and the
combined end point of death, reinfarction or stroke (33.1%
[45 of 136 patients] vs. 34.5% [92 of 267 patients]) (OR
0.94, 95% CI 0.61 to 1.46).
DISCUSSION
Acute myocardial infarction occurring in patients who have
already been admitted to the hospital (in-hospital infarc-
tion) is an entity that is poorly described in medical data. A
search in Medline from 1980 to 1999 revealed only two
articles dealing with this subject (9,10). Both were retro-
spective and described the results of ;50 patients with an
in-hospital AMI. However, this subgroup of patients might
be of important clinical interest, because they give us the
chance to know what could be achieved with current therapy
in patients with AMI, if all patients with AMI reached the
hospital alive.
Prevalence and characteristics of patients with an in-
hospital AMI. The prevalence of in-hospital infarction
was 6.8% (403 of 5,888) of the patients with AMI in the
prospective MITRA trial. In-hospital infarctions occurred
with a median delay of 2.5 days after admission to the
hospital. Zmyslinski et al. (9) reported a 9.8% rate (50 of
510) of patients with in-hospital infarctions, and L’Abbate
et al. (10) reported a 2% to 3% incidence for patients with
in-hospital Q wave in-hospital AMI. The low incidence
reported by L’Abbate et al. (10) is likely attributed to the
population for which it was given. This 2% to 3% incidence
for Q wave in-hospital AMIs has been reported for patients
with documented ischemia at rest during the same hospital
period. In our study, patients with in-hospital infarctions
were older and sicker as compared with patients with
prehospital infarctions. They also more often had a history
of diabetes mellitus and arterial hypertension, as well as a
Table 3. Clinical Events During the Hospital Period
In-Hospital
Infarction Group
(n 5 403)
Prehospital
Infarction Group
(n 5 5,485)
Odds Ratio (95%
CI) or p Value
Bleeding (gastrointestinal or
with need of transfusion)
15/403 (3.7%) 76/5,485 (1.4%) 2.75 (1.57–4.83)
Minor stroke 0/403 (0%) 54/5,485 (1%) 0.12 (0.01–2.0)
Major stroke 11/403 (2.7%) 101/5,485 (1.8%) 1.50 (0.80–2.81)
Heart failure (NYHA class III) 106/403 (26.3%) 1,074/5,485 (19.6%) 1.47 (1.16–1.85)
Postinfarction angina 67/403 (16.6%) 806/5,485 (14.7%) 1.16 (0.88–1.52)
Reinfarction 31/403 (7.7%) 258/5,485 (4.7%) 1.69 (1.15–2.49)
Urgent CABG/angioplasty 56/333 (16.8%) 538/4,787 (11.2%) 1.58 (1.18–2.16)
In-hospital death 110/403 (27.3%) 762/5,485 (13.9%) 2.33 (1.85–2.94)
Combined end point (death,
reinfarction or any stroke)
137/403 (34%) 1,018/5,485 (18.6%) 2.26 (1.82–2.81)
Data are presented as number (%) of patients.
CABG 5 coronary artery bypass graft surgery; CI 5 confidence interval; NYHA 5 New York Heart Association.
Table 4. In-Hospital Death and Combined End Point in Patients With In-Hospital Myocardial
Infarction (n 5 403): Relation to Reperfusion Therapy
Reperfusion Therapy
In-Hospital Death
(n 5 110 [27.3%])
Combined End Point
(n 5 137 [34%])
None (i.e., conservative) 61/175 (34.9%) 69/175 (39.4%)
Any reperfusion therapy 49/228 (21.5%) 68/228 (29.8%)
Intravenous
thrombolysis
44/178 (24.7%) 61/178 (34.3%)
Primary angioplasty 4/40 (10%) 5/40 (12.5%)
Thrombolysis and
angioplasty
1/10 (10%) 2/10 (20%)
Data are presented as number (%) of patients.
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higher prevalence of renal insufficiency and contraindica-
tions for thrombolysis. These findings are in concordance
with the patient description made by Zmyslinski et al. (9).
Admission diagnosis. Evaluation of the admission diag-
nosis in patients with an in-hospital AMI was not part of
the initial protocol of the MITRA registry. To get an
impression of the categories of patients with in-hospital
infarctions, four hospitals agreed to perform a chart review
of their patients with an in-hospital AMI to look for the
admission diagnosis. As expected, the majority of patients
with an in-hospital AMI were admitted to the hospital with
stable or unstable angina pectoris (72.8%). Only a minority
of patients with an in-hospital AMI had their infarction
after operation (8%).
Clinical course. The hospital mortality rate was 27.3%
(110 of 403) for patients with an in-hospital AMI versus
13.9% (762 of 5,485) for patients with a prehospital AMI
(OR 2.33, 95% CI 1.85 to 2.94). This difference remained
significant after performing a logistic regression analysis
adjusting for other confounding variables (OR 1.54, 95% CI
1.28 to 1.86). The same was shown for the combined end
point of death, reinfarction or stroke. This death rate of
27.3% is close to the 29% death rate reported by L’Abbate
et al. in 1986 (10), but is much lower than the 66% death
rate reported by Zmyslinski et al. in 1981 (9). Although the
number of patients in both studies was small, the difference
between the 1981 data and the 1986 data may reflect better
treatment (reperfusion therapy and adjunctive therapy) in
these patients.
Patients with an in-hospital AMI were less often treated
with beta-blockers (44% vs. 53.7%; OR 0.68, 95% CI 0.56
to 0.84), as well as with heparin, nitroglycerin and aspirin.
This may be mainly explained by different patient charac-
teristics. However, the proportion of patients receiving no
reperfusion therapy (primary angioplasty, thrombolysis or a
combination of thrombolysis and angioplasty) was not
different between the two groups (in-hospital AMI 43.4%
vs. prehospital AMI 41.7%; OR 1.07, 95% CI 0.88 to 1.32).
Patients with an in-hospital AMI more often had contra-
indications for thrombolysis. Therefore, the proportion of
patients regarded as thrombolytic eligible was significantly
lower in the in-hospital AMI group (59.3% vs. 74.3%; OR
0.51, 95% CI 0.41 to 0.62). However, even in patients
eligible for thrombolysis, 30% were not treated with reper-
fusion therapy, with no difference between prehospital and
in-hospital infarctions. This rate is close to the 24% rate in
thrombolytic-eligible patients reported in the National Reg-
istry of Myocardial Infarction-2 study (12), which also did
not use reperfusion therapy. Barron et al. (12), as well as
Wagner et al., on behalf of the Myocardial Infarction
Registry Investigators (13), found that age .70 years,
female gender, presence of left bundle branch block, pre-
hospital delays .6 h and various preexisting cardiovascular
conditions were independent predictors that even
thrombolytic-eligible patients would not receive reperfusion
therapy. In patients with contraindications for thrombolysis,
primary angioplasty should be the ideal reperfusion therapy
(14–18). Our data show that primary angioplasty seems not
to be used properly in this subgroup of patients with AMI,
and hospitals without the facilities to perform primary
angioplasty should transfer such patients, which is safe and
effective (19–23).
The interval from the onset of symptoms to the start of
the treatment in patients treated with reperfusion therapy
was 55 min (median) for patients with an in-hospital AMI
versus 180 min (median) for patients with a prehospital
AMI (p 5 0.001). This shows that patients with an
in-hospital AMI are quickly recognized, and time to reper-
fusion therapy is quite short.
Hospitals with and without angioplasty facilities. At
hospitals with the facilities to perform angioplasty, there
was a higher proportion of patients with in-hospital infarc-
tions of all patients with AMI, as compared with hospitals
without such facilities (7.9% [136 of 1,717] vs. 6.4% [267 of
4,171]) (OR 1.26, 95% CI 1.02 to 1.56). This could result
from a combination of selection of patients, because many
patients with unstable or stable coronary syndromes will be
sent to hospitals with the facilities to perform angioplasty,
and the possible consequences of such interventions, such as
AMI due to dissections or stent thrombosis after coronary
balloon angioplasty. However, the proportion of patients
with an in-hospital AMI not treated with reperfusion
therapy was slightly but not significantly lower at hospitals
with angioplasty facilities (38.2%) as compared with hospi-
tals without such facilities (46.1%; OR 0.73, 95% CI 0.48 to
1.10), even in lytic-eligible patients (33% vs. 31%; OR 1.10,
95% CI 0.63 to 1.91), although primary angioplasty has
been used more frequently (25.7% vs. 1.9%; OR 18.2, 95%
CI 6.92 to 47.65). Nevertheless, hospital mortality for
patients with an in-hospital AMI was similar at both types
of hospitals (26.5% vs. 27.7%; OR 0.94, 95% CI 0.59 to
1.50), as well as for the combined end point (33.1% vs.
34.5%; OR 0.94, 95% CI 0.61 to 1.46). However, the high
mortality rate of patients with an in-hospital AMI, in
combination with the relative low use of reperfusion ther-
apy, even at hospitals with the facilities to perform angio-
plasty, should encourage each hospital to review their cases
and to try to improve the management of these patients.
In-hospital infarction as a clinical model of the popula-
tion view of case fatality in patients with AMI. The
observed case fatality rate of 27.3% for patients with an
in-hospital AMI is much lower than the 50% case fatality
rate for the population reported by the Multinational
MONitoring of Trends and Determinants in CArdiovas-
cular Disease (MONICA) project (1), but it is also higher
than the 13.9% case fatality rate for patients with a prehos-
pital AMI reaching the hospital alive in our study. As
L’Abbate et al. (10) showed, this relatively low mortality
rate for patients with an in-hospital AMI can be attributed
to the proportion of patients who had a cardiac arrest and
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were successfully resuscitated. However, we found no dif-
ference in the number of resuscitated patients between
in-hospital AMI and prehospital AMI (8.3% vs. 6.3%; OR
1.30, 95% CI 0.84 to 2.01). However, the in-hospital AMI
subgroup may not be representative of the population
developing AMI. A majority of patients with an in-hospital
AMI might be admitted with preexisting clinical evidence
of ischemic heart disease or may be suffering from other
clinically relevant diseases, which made hospital admission
necessary. Another possible explanation for the still high
mortality might be that electrical instability may be respon-
sible for a smaller than expected proportion of sudden
deaths outside the hospital, as well as a higher rate than
expected due to left ventricular failure or shock.
Study limitations. Admission diagnosis was evaluated ret-
rospectively in only 88 (21.8%) of 403 patients with an
in-hospital AMI. Therefore, the reported percentages are
giving only an impression of the categories of patients with
an in-hospital AMI. We also did not collect information on
the proportion of patients with postprocedural (coronary
balloon angioplasty, stents) in-hospital AMI. In contrast to
the MONICA project, we collected only information of
clinically diagnosed AMIs, not of all patients who died
suddenly during their hospital stay and were not treated at
the intensive care unit.
Conclusions. In-hospital infarction, which comprises up
to 7% of all AMIs, is a poorly analyzed entity. Most patients
with an in-hospital infarction (72.8%) are admitted because
of stable or unstable angina pectoris. Mortality and mor-
bidity are high in patients with an in-hospital AMI, even
after adjusting for other confounding variables. Contraindi-
cations for thrombolysis are more prevalent in these pa-
tients; however, primary angioplasty, which should be the
method of choice in these circumstances, is currently unde-
rused.
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